Novartis News | finanzen.ch

Novartis Aktie VALOR 1200526 / ISIN CH0012005267

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

28.08.15	Novartis continues commitment to go the last mile in effort to eliminate leprosy (GlobeNewswire)
24.08.15	FDA expands use of Novartis drug Promacta® to include treatment of children ages 1 and older with chronic immune thrombocytopenia (GlobeNewswire)
21.08.15	Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications (GlobeNewswire)
20.08.15	Novartis drug Odomzo® gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients (GlobeNewswire)
03.08.15	Novartis completes divestiture of influenza vaccines business to CSL Limited for USD 275 million (GlobeNewswire)
29.07.15	Novartis partners with Phase 4 Partners and institutional investors to help create Mereo BioPharma Group Ltd (GlobeNewswire)
27.07.15	Novartis Foundation confirms new members of its Board of trustees, including new Chairman Dr. Joerg Reinhardt (GlobeNewswire)
27.07.15	Novartis Stiftung bestätigt neue Mitglieder des Stiftungsrats und Dr. Jörg Reinhardt als neuen Vorsitzenden (GlobeNewswire)
24.07.15	FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer (GlobeNewswire)
24.07.15	Novartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestones (GlobeNewswire)
21.07.15	Novartis erzielt im zweiten Quartal eine solide Performance mit starken Innovationen und Fortschritten bei Neueinführungen (GlobeNewswire)
21.07.15	Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches (GlobeNewswire)
16.07.15	Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patients (GlobeNewswire)
07.07.15	Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization (GlobeNewswire)
01.07.15	Alcon receives European Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery (GlobeNewswire)
30.06.15	Novartis Pharmaceuticals launches the first app for visually impaired people for use with the Apple Watch and other smart watches (GlobeNewswire)
29.06.15	Novartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc. (GlobeNewswire)
29.06.15	Novartis announces publication in The Lancet showing sustained efficacy with secukinumab over one year in psoriatic arthritis patients (GlobeNewswire)
26.06.15	Novartis drug Farydak® recommended by CHMP for EU approval to treat multiple myeloma, providing patients a new mechanism of action (GlobeNewswire)
18.06.15	Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone® 20mg (GlobeNewswire)
18.06.15	Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day (GlobeNewswire)
16.06.15	Alcon receives European approval for new trifocal presbyopia-correcting intraocular lens for patients undergoing cataract surgery (GlobeNewswire)
13.06.15	Novartis presents new data from large European study reinforcing the benefit of first-line Tasigna® in newly-diagnosed patients with CML (GlobeNewswire)
13.06.15	Novartis announces data show majority of patients with polycythemia vera treated with Jakavi® achieved long-term disease control (GlobeNewswire)
12.06.15	Novartis data at EHA show increased PFS benefit of Farydak® in new subgroup of patients with previously treated multiple myeloma (GlobeNewswire)
12.06.15	Novartis drug Arzerra® improved median progression-free survival by 54% in patients with relapsed chronic lymphocytic leukemia (GlobeNewswire)
12.06.15	Novartis reports new analysis showing Xolair® improving quality of life by 78% for chronic spontaneous urticaria patients (GlobeNewswire)
11.06.15	Novartis gains FDA approval for Promacta® providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder (GlobeNewswire)
11.06.15	Novartis presents new data at WCD demonstrating significant efficacy of Cosentyx® in patients with psoriasis of the nails, palms and soles (GlobeNewswire)
10.06.15	Novartis announces new one-year results demonstrating sustained secukinumab efficacy in ankylosing spondylitis patients (GlobeNewswire)
02.06.15	Novartis presents new data at EULAR and WCD further demonstrating its leadership in severe long-term inflammatory and skin conditions (GlobeNewswire)
01.06.15	Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma (GlobeNewswire)
01.06.15	Novartis presents new data at ASCO for Zykadia® and combination of Tafinlar® and Mekinist® in certain NSCLC patients with unmet needs (GlobeNewswire)
31.05.15	Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma (GlobeNewswire)
27.05.15	Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA (GlobeNewswire)
21.05.15	Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors (GlobeNewswire)
20.05.15	Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237 (GlobeNewswire)
08.05.15	Novartis lung cancer drug Zykadia® gains EU approval, providing new therapy for certain patients with ALK+ NSCLC (GlobeNewswire)
27.04.15	Novartis announces Phase III study of Arzerra® met primary endpoint of improved progression-free survival in patients with relapsed CLL (GlobeNewswire)
23.04.15	Novartis erzielt im ersten Quartal[1] Umsatzsteigerungen (kWk), deutlich höhere Margen (kWk) und beachtliche Innovationen - jetzt mit einem stärker fokussierten Portfolio (GlobeNewswire)
23.04.15	Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more focused portfolio (GlobeNewswire)
21.04.15	Data at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients (GlobeNewswire)
16.04.15	Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mg (GlobeNewswire)
16.04.15	Alcon receives FDA approval of new multifocal intraocular lens to treat cataract patients in the United States (GlobeNewswire)
15.04.15	Data in The Lancet show Novartis drug Arzerra® plus chlorambucil improved median progression-free survival by 71% in CLL patients (GlobeNewswire)
13.04.15	Gilenya® data at AAN to highlight Novartis leadership in innovation with new MS assessment methods to benefit patients and physicians (GlobeNewswire)
30.03.15	Novartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overload (GlobeNewswire)
30.03.15	Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group (GlobeNewswire)
21.03.15	Novartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in psoriasis patients (GlobeNewswire)
20.03.15	New Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patients (GlobeNewswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swiss Life Hldg	812.40	0.45 %	K V
Geberit	552.80	0.36 %	K V
Swisscom	513.50	0.20 %	K V
Logitech Intl	75.48	0.13 %	K V
Givaudan	3’825.00	0.05 %	K V
Part Grp Hldg	1’246.00	-1.35 %	K V
Novartis	96.82	-1.63 %	K V
Sonova Hldg	252.10	-1.68 %	K V
Lonza Grp	532.00	-1.77 %	K V
Roche Hldg G	286.80	-1.92 %	K V

mehr

02.04.25		Roche-Aktie: Roche treibt Krebsdiagnostik mit Next Generation Sequencing voran
02.04.25		Börse New York in Grün: Dow Jones zum Ende des Mittwochshandels auf grünem Terrain
02.04.25		Dow Jones aktuell: Dow Jones im Plus
02.04.25		Pluszeichen in New York: Dow Jones mittags freundlich
02.04.25		Minuszeichen in Zürich: SPI zum Ende des Mittwochshandels im Minus
02.04.25		Schwacher Handel in Europa: STOXX 50 beendet den Mittwochshandel im Minus